Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Chronic Cough Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Chronic Cough Overview | 8 | 1 |
| Pipeline Products for Chronic Cough Comparative Analysis | 9 | 1 |
| Chronic Cough Therapeutics under Development by Companies | 10 | 1 |
| Chronic Cough Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Chronic Cough Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Chronic Cough Products under Development by Companies | 14 | 1 |
| Chronic Cough Products under Investigation by Universities/Institutes | 15 | 1 |
| Chronic Cough Companies Involved in Therapeutics Development | 16 | 9 |
| Afferent Pharmaceuticals, Inc. | 16 | 1 |
| AstraZeneca Plc | 17 | 1 |
| Conrig Pharma ApS | 18 | 1 |
| GlaxoSmithKline Plc | 19 | 1 |
| Glenmark Pharmaceuticals Ltd. | 20 | 1 |
| GW Pharmaceuticals Plc | 21 | 1 |
| NeRRe Therapeutics Ltd | 22 | 1 |
| Patara Pharma, Inc. | 23 | 1 |
| Pila Pharma AB | 24 | 1 |
| Chronic Cough Therapeutics Assessment | 25 | 8 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 1 |
| Drug Profiles | 33 | 18 |
| AF-219 Drug Profile | 33 | 4 |
| cromolyn sodium Drug Profile | 37 | 1 |
| GRC-17536 Drug Profile | 38 | 2 |
| GSK-2339345 Drug Profile | 40 | 1 |
| lesogaberan Drug Profile | 41 | 1 |
| NEO-5937 Drug Profile | 42 | 1 |
| orvepitant maleate Drug Profile | 43 | 2 |
| S-1226 Drug Profile | 45 | 2 |
| Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases Drug Profile | 47 | 1 |
| ST-015 Drug Profile | 48 | 1 |
| XEND-0501 Drug Profile | 49 | 2 |
| Chronic Cough Dormant Projects | 51 | 1 |
| Chronic Cough Discontinued Products | 52 | 1 |
| Chronic Cough Product Development Milestones | 53 | 7 |
| Featured News &Press Releases | 53 | 1 |
| Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis | 53 | 1 |
| May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference | 54 | 2 |
| May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors | 56 | 1 |
| Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial | 56 | 1 |
| Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet | 57 | 1 |
| Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company s Lead P2X3 Antagonist, AF-219 | 58 | 2 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |